$ News

Adrenoleukodystrophy Market Research 2025-2035 | Minoryx and Neuraxpharm Achieve Milestone in cALD Treatment with Leriglitazone

bluebird bio Strengthens Leadership Team With New Appointments

bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital

bluebird bio, Inc. (BLUE) Nears Acquisition by Carlyle and SK Capital

Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer

bluebird bio Reminds Stockholders to Act Now to Tender Shares for Acquisition by Carlyle and SK Capital

High Noon For bluebird

Carlyle, SK Capital Partners and bluebird bio Provide Updated Tender Instructions

Bluebird Bio (BLUE) Reports Q1 Loss, Lags Revenue Estimates

Bluebird: Q1 Earnings Snapshot

Bluebird Bio Shareholders Get New All-Cash Offer From Private Equity

Carlyle, SK Capital Partners and bluebird bio Amend Merger Agreement

Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital

Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio

bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement

Bluebird bio receives non-binding bid for up to $110.5 million

Bluebird Bio Gets Rival Buyout Proposal From Ayrmid; Shares Jump After Hours

bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid

Bluebird Bio (BLUE) Reports Q4 Loss, Tops Revenue Estimates

Carlyle's bluebird Deep Discount Buyout (Rating Upgrade)